Literature DB >> 25767071

Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS).

M-C Amigo1, M V Goycochea-Robles2, G Espinosa-Cuervo3, G Medina4, J A Barragán-Garfias5, A Vargas6, L Javier Jara7.   

Abstract

INTRODUCTION: In antiphospholipid syndrome (APS), certain principal manifestations are associated with a worse prognosis and organ damage.
OBJECTIVE: The objective of this paper is to describe the development and initial content, criterion and construct validity of a disease-specific cumulative damage index in patients with thrombotic APS (DIAPS).
METHODS: Through expert panel agreement, 47 items were considered to reflect damage in APS. This preliminary version of the DIAPS was submitted to four local and international clinical and research experts in APS who ranked each item according to severity. A Delphi exercise resulted in a final 37 item instrument. In the second phase, a cross-sectional study was conducted applying the DIAPS in patients included in a multicenter electronic registry of patients with APS. Quality of life related to health status was evaluated with the EuroQol for construct validation. An α Cronbach and correlation with the EuroQol scale were calculated with SPSS 20.0 (p < 0.05).
RESULTS: We evaluated the DIAPS in 156 patients, 77% female, with a mean age at diagnosis 34.7 ± 5.5 years. A total of 69% had primary APS. Common comorbidities included obesity, depression and dyslipidemia. The most frequent manifestations resulting in sequelae were deep venous thrombosis and ischemic stroke. Blindness, retinal occlusive vessel disease, myocardial infarction, cardiac valve requiring replacement, mesenteric thrombosis, and renal insufficiency also occurred. Homogeneity: α Cronbach 0.619. DIAPS items correlated with EuroQol domains with the exception of pulmonary, renal, gastrointestinal, and endocrine systems.
CONCLUSION: This study demonstrates content, criterion and construct validity of a new physician-reported instrument to assess the DIAPS. In addition, the DIAPS correlated with the EuroQol.
© The Author(s) 2015.

Entities:  

Keywords:  Antiphospholipid syndrome; Damage index; Hughes syndrome

Mesh:

Substances:

Year:  2015        PMID: 25767071     DOI: 10.1177/0961203315576858

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  10 in total

Review 1.  An Update on Antiphospholipid Syndrome.

Authors:  Eleni Xourgia; Maria G Tektonidou
Journal:  Curr Rheumatol Rep       Date:  2022-01-05       Impact factor: 4.592

Review 2.  Organ Damage and Quality of Life in Antiphospholipid Syndrome.

Authors:  P Alba; J A Gómez-Puerta; M V Goycochea-Robles; M C Amigo
Journal:  Curr Rheumatol Rep       Date:  2016-02       Impact factor: 4.592

Review 3.  Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances.

Authors:  Savino Sciascia; Mary-Carmen Amigo; Dario Roccatello; Munther Khamashta
Journal:  Nat Rev Rheumatol       Date:  2017-08-03       Impact factor: 20.543

4.  miR-19b-3p and miR-20a-5p are associated with the levels of antiphospholipid antibodies in patients with antiphospholipid syndrome.

Authors:  Y Juárez-Vicuña; C A Guzmán-Martín; L A Martínez-Martínez; A Hernández-Díazcouder; C Huesca-Gómez; R Gamboa; L M Amezcua-Guerra; M Chacon-Perez; M C Amigo; F Sánchez-Muñoz
Journal:  Rheumatol Int       Date:  2021-04-23       Impact factor: 2.631

Review 5.  Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update.

Authors:  Doruk Erkan; Savino Sciascia; Maria Laura Bertolaccini; Hannah Cohen
Journal:  Curr Rheumatol Rep       Date:  2021-05-01       Impact factor: 4.592

Review 6.  Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects.

Authors:  Aline Garcia Islabão; Vitor Cavalcanti Trindade; Licia Maria Henrique da Mota; Danieli Castro Oliveira Andrade; Clovis Artur Silva
Journal:  Paediatr Drugs       Date:  2021-12-13       Impact factor: 3.022

7.  Pediatric antiphospholipid syndrome: clinical features and therapeutic interventions in a single center retrospective case series.

Authors:  Jacqueline A Madison; Kelsey Gockman; Claire Hoy; Ajay Tambralli; Yu Zuo; Jason S Knight
Journal:  Pediatr Rheumatol Online J       Date:  2022-02-23       Impact factor: 3.054

8.  Sirolimus Monotherapy for Thrombocytopenia in Primary Antiphospholipid Syndrome: A Pilot Study From a Tertiary Referral Center.

Authors:  Wenhui Xie; Lanlan Ji; Zhuoli Zhang
Journal:  Front Immunol       Date:  2022-03-25       Impact factor: 7.561

9.  Thrombocytopenia in a cohort of primary and secondary antiphospholipid syndrome patients: Relation to clinical, laboratory manifestations and damage index.

Authors:  Sherif Gamal; Samar Mohamed; Abdelkawy Moghazy
Journal:  Arch Rheumatol       Date:  2022-01-23       Impact factor: 1.007

10.  Vasculitis damage index in Behçet's disease.

Authors:  Fatema T Elgengehy; Sherif M Gamal; Nesreen Sobhy; Ibrahem Siam; Ahmed M Soliman; Ghada W Elhady; Tamer A Gheita
Journal:  Adv Rheumatol       Date:  2021-06-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.